Skip to content
value.today

Landos Biopharma, Inc.

🇺🇸 Blacksburg, Virginia, USABiotechnologyFounded 2017
Total raised
$60 M
1 round on record
Latest round
$60 M
Aug 2019
First round on record
Aug 2019
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Landos Biopharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2019$60 MNo. 1$50 to $250 million

Landos Biopharma, Inc.: Raise no. 1, Aug 2019

Investors in this round

10 investors had bought by the notice of Aug 23, 2019: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Landos Biopharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$60 M of $60 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Josep Bassaganya-Riera · Executive Officer, Director
  • Christopher Garabedian · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Josep Bassaganya-Riera, President. Newest notice filed Aug 23, 2019. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Landos Biopharma, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2019).

    SEC Form D · Aug 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2019

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

2 named in official filings. Open an investor to see everything it has backed.

Investors in Landos Biopharma, Inc.
InvestorKindAmountRoundRoleSource
Nomura Healthcare FundFund or asset manager$0 Mheldnot statedHolds shares (fund report, Jun 2026)SEC Form N-PORT
The Gabelli ABC FundFund or asset manager$0 Mheldnot statedHolds shares (fund report, Jun 2026)SEC Form N-PORT

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Landos Biopharma, Inc.
NameRoleNamed in
Josep Bassaganya-RieraExecutive officerAug 2019
Christopher GarabedianDirectorAug 2019
Josep Bassaganya-RieraDirectorAug 2019